Congruence Therapeutics, a Canada-based biotechnology company, announced on Tuesday that it has named Sharath S Hegde, PhD as its new chief scientific officer.

Dr Hegde has served as chief scientific officer at Herophilus and chief scientific officer of Recursion. He has spent more than 15 years at Theravance Biopharma, where he rose from positions of increasing responsibility to assume the role of senior vice president and head of Research. He has served at Syntex Corporation for nine years.

Dr Hegde has PhD in Pharmacology from the University of Houston and B.Pharm/M.Pharm from the University of Mumbai.